Kimberly Mayumi Komatsubara
Gilead Sciences (United States) · 66 works · 3,018 citations · h-index 17
Top works
- Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
- Uveal melanoma: epidemiology, etiology, and treatment of primary disease
- IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC
- Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC
- Application of Plasma Genotyping Technologies in Non–Small Cell Lung Cancer: A Practical Review
- Clinical Management of Uveal and Conjunctival Melanoma.
- Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies
- The promise and challenges of rare cancer research
- Hepatotoxin-Induced Changes in the Adult Murine Liver Promote MYC-Induced Tumorigenesis
- A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma
- Sacituzumab govitecan in HR+HER2− metastatic breast cancer: the randomized phase 3 EVER-132-002 trial
- Low-level shRNA Cytotoxicity Can Contribute to MYC-induced Hepatocellular Carcinoma in Adult Mice
- The Role of Oncolytic Viruses in the Treatment of Melanoma
- Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers
- Circulating Tumor DNA as a Liquid Biopsy: Current Clinical Applications and Future Directions.
- Selumetinib for the Treatment of Metastatic Uveal Melanoma: Past and Future Perspectives
- Phase ib/2a study of PLX51107, a small molecule BET inhibitor, in subjects with advanced hematological malignancies and solid tumors.
- Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma
- Exposure to a Histone Deacetylase Inhibitor Has Detrimental Effects on Human Lymphocyte Viability and Function
- FP13.03 IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1–Selected NSCLC